Ipilimumab (trade name: Yervoy), a CTLA-4 inhibitor, was first introduced for the treatment of metastatic melanoma while tremelimumab, another CTLA-4 inhibitor, was initially explored for its efficacy in malignant mesothelioma. The gene discussed is CTLA4; the disease is metastatic melanoma.